BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of cardiovascular disease. This study was conducted to describe the distribution of Lp-PLA2 in a cohort of human immunodeficiency virus (HIV)-infected adults and to determine associations between Lp-PLA2, cardiometabolic risk factors, and subclinical atherosclerosis in this population. METHODS: Lp-PLA2 was assessed in 341 (25% women, 52% white, 74% on highly active antiretroviral therapy [HAART]) participants of a cohort with detailed characterization of atherogenic risk factors, including surrogate markers of carotid and coronary atherosclerosis. RESULTS: Mean Lp-PLA2 mass was 313 ± 105 ng/mL and activity 173 ± 49 nmol/minute/mL. Seventy-five percent of participants had abnormal Lp-PLA2. Those in the highest Framingham Risk Score tertile had significantly higher Lp-PLA2 activity. Participants with abnormal carotid intima-media thickness (cIMT) had higher Lp-PLA2 mass and activity. Those with coronary artery calcium (CAC) scores >100 had significantly higher Lp-PLA2 mass than those with lower or nondetectable calcium. Those on HAART and protease inhibitor (PI)-based treatment had significantly higher Lp-PLA2 mass and activity than those who were treatment-naive or not on PIs. In multivariate regression, HAART and PI use were positively associated with Lp-PLA2 activity and mass after adjusting for age, race, sex, low-density and high-density lipoprotein cholesterol levels, triglyceride level, and smoking. Adding Lp-PLA2 activity tertiles to the model improved the predictive value for abnormal common cIMT, but not internal cIMT or CAC score. CONCLUSIONS: Lp-PLA2 is highly abnormal in HIV-infected patients and is associated with several cardiovascular and HIV treatment-specific risk factors. Lp-PLA2 may be used as an additional and more vascular specific biomarker for cardiovascular risk stratification in HIV-positive patients.
BACKGROUND:Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of cardiovascular disease. This study was conducted to describe the distribution of Lp-PLA2 in a cohort of human immunodeficiency virus (HIV)-infected adults and to determine associations between Lp-PLA2, cardiometabolic risk factors, and subclinical atherosclerosis in this population. METHODS:Lp-PLA2 was assessed in 341 (25% women, 52% white, 74% on highly active antiretroviral therapy [HAART]) participants of a cohort with detailed characterization of atherogenic risk factors, including surrogate markers of carotid and coronary atherosclerosis. RESULTS: Mean Lp-PLA2 mass was 313 ± 105 ng/mL and activity 173 ± 49 nmol/minute/mL. Seventy-five percent of participants had abnormal Lp-PLA2. Those in the highest Framingham Risk Score tertile had significantly higher Lp-PLA2 activity. Participants with abnormal carotid intima-media thickness (cIMT) had higher Lp-PLA2 mass and activity. Those with coronary artery calcium (CAC) scores >100 had significantly higher Lp-PLA2 mass than those with lower or nondetectable calcium. Those on HAART and protease inhibitor (PI)-based treatment had significantly higher Lp-PLA2 mass and activity than those who were treatment-naive or not on PIs. In multivariate regression, HAART and PI use were positively associated with Lp-PLA2 activity and mass after adjusting for age, race, sex, low-density and high-density lipoprotein cholesterol levels, triglyceride level, and smoking. Adding Lp-PLA2 activity tertiles to the model improved the predictive value for abnormal common cIMT, but not internal cIMT or CAC score. CONCLUSIONS:Lp-PLA2 is highly abnormal in HIV-infectedpatients and is associated with several cardiovascular and HIV treatment-specific risk factors. Lp-PLA2 may be used as an additional and more vascular specific biomarker for cardiovascular risk stratification in HIV-positivepatients.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: Patrick Mercié; Rodolphe Thiébaut; Valérie Lavignolle; Jean-Luc Pellegrin; Marie-Christine Yvorra-Vives; Philippe Morlat; Jean-Marie Ragnaud; Michel Dupon; Denis Malvy; Hélène Bellet; Sylvie Lawson-Ayayi; Raymond Roudaut; Françios Dabis Journal: Ann Med Date: 2002 Impact factor: 4.709
Authors: Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett Journal: Circulation Date: 2004-02-02 Impact factor: 29.690
Authors: Priscilla Y Hsue; Joan C Lo; Arlana Franklin; Ann F Bolger; Jeffrey N Martin; Steven G Deeks; David D Waters Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245
Authors: Suman Srinivasa; Kathleen V Fitch; Martin Torriani; Markella V Zanni; Christopher Defilippi; Robert Christenson; Patrick Maehler; Sara E Looby; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Mabel Toribio; Kathleen V Fitch; Laura Sanchez; Tricia H Burdo; Kenneth C Williams; Craig A Sponseller; Mary McCurdy Pate; Judith A Aberg; Markella V Zanni; Steven K Grinspoon Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Daniel E Nixon; Ronald J Bosch; Ellen S Chan; Nicholas T Funderburg; Sally Hodder; Jordan E Lake; Michael M Lederman; Karin L Klingman; Judith A Aberg Journal: J Clin Lipidol Date: 2016-10-05 Impact factor: 4.766
Authors: Leangelo N Hall; Laura R Sanchez; Jane Hubbard; Hang Lee; Sara E Looby; Suman Srinivasa; Markella V Zanni; Takara L Stanley; Janet Lo; Steven K Grinspoon; Kathleen V Fitch Journal: Open Forum Infect Dis Date: 2017-04-24 Impact factor: 3.835
Authors: Mabel Toribio; Kathleen V Fitch; Lauren Stone; Markella V Zanni; Janet Lo; Chris de Filippi; Craig A Sponseller; Hang Lee; Ida Grundberg; Melanie A Thompson; Judith A Aberg; Steven K Grinspoon Journal: EBioMedicine Date: 2018-08-31 Impact factor: 8.143
Authors: Alinda G Vos; Nikmah S Idris; Roos E Barth; Kerstin Klipstein-Grobusch; Diederick E Grobbee Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240